Here’s a mechanistic way to think about why ZR‑75‑1 (an ER+ luminal breast cancer line) is unusually sensitive to ASH1L knockout, tying together its strong CRISPR dependencies and the mutations you listed.

Executive summary
- ASH1L writes the activating chromatin mark H3K36me2 at promoters/enhancers, which directly antagonizes PRC2/EZH2‑mediated H3K27me3 and helps keep lineage programs “on.” Knocking out ASH1L removes this barrier, allowing Polycomb repression to spread and collapse lineage‑critical transcription programs. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21239496/?utm_source=openai))
- ZR‑75‑1’s top dependencies are dominated by chromatin and lineage regulators (TRPS1, ASF1B, BRPF1, PRDM4), consistent with an epigenetically “fragile” luminal state that needs continuous chromatin support; removing ASH1L is therefore catastrophic. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30380416/?utm_source=openai))
- Multiple mutations in the MLL/COMPASS axis (MEN1 frameshift; WDR5 and KMT2B variants) can weaken H3K4‑based activation and increase reliance on ASH1L’s H3K36me2 to sustain transcription. In that context, ASH1L loss is especially lethal. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3741089/?utm_source=openai))

How ASH1L supports luminal breast cancer fitness
- What ASH1L does: Mammalian ASH1L is a trithorax‑group histone methyltransferase that deposits H3K36me2 at active regulatory regions. H3K36 methylation blocks PRC2 catalysis in cis, preventing H3K27me3 from spreading into active chromatin; removing H3K36me2 lets PRC2 encroach and silence genes. This H3K36–H3K27 antagonism is well‑established biochemically and in vivo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21239496/?utm_source=openai))
- Where ASH1L acts: Newer mapping shows ASH1L’s catalytic activity is concentrated at regulatory elements of developmentally relevant genes (distinct from the broad intergenic H3K36me2 laid down by NSD1/2/3). Thus, cells that depend on lineage‑defining transcription factors are poised to suffer if ASH1L is lost. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37905045/?utm_source=openai))
- Cooperation with MLL/LEDGF: The H3K36me2 written by ASH1L is read by LEDGF and helps recruit/maintain MLL complexes at key targets; ASH1L is required for full expression of MLL targets (e.g., HOX, MEIS) and its catalytic activity is functionally important in cancer models. Although demonstrated most clearly in leukemia, the mechanism is general: H3K36me2 promotes MLL‑dependent transcription. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27154821/?utm_source=openai))

Why ZR‑75‑1 looks “extra” dependent on ASH1L given its dependencies
- TRPS1 is a top hit in ZR‑75‑1 and a known luminal breast cancer lineage dependency. TRPS1 reshapes chromatin, modulates ERα binding, and controls cell‑cycle gene expression; luminal lines are particularly vulnerable to TRPS1 loss. A lineage circuit like TRPS1→ER programs needs an open, PRC2‑resistant chromatin environment—exactly what ASH1L’s H3K36me2 helps provide. Removing ASH1L likely undermines TRPS1/ER circuitry, explaining the strong drop in fitness. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30380416/?utm_source=openai))
- BRPF1 (another top hit) is the scaffold of the KAT6A/KAT6B (MOZ/MORF) acetyltransferase complexes that acetylate/propionylate H3 tails (notably H3K23), mark active chromatin, and support enhancer activity. Co‑dependence on ASH1L and BRPF1 points to a state reliant on multiple, cooperating pro‑transcription chromatin writers; losing one (ASH1L) can trigger collapse. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9454415/?utm_source=openai))
- ASF1B (top‑10 hit) is the S‑phase H3–H4 chaperone that promotes new histone acetylation and chromatin assembly; strong ASF1B dependence plus BRPF1 dependence together suggest that ZR‑75‑1 proliferation is tightly coupled to chromatin maturation—making it hypersensitive to any writer (like ASH1L) that keeps repressive PRC2 out of active domains. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17107956/?utm_source=openai))

Why the mutation profile can intensify ASH1L addiction
- MEN1 frameshift (p.I457Ter): Menin is the scaffold that tethers MLL1/MLL2 (KMT2A/KMT2B) complexes to chromatin; menin/MLL activity sustains key gene programs (canonical in leukemia, but the complex is broadly used). A truncating MEN1 mutation likely weakens MLL/menin‑dependent H3K4 trimethylation. Cells with compromised MLL/menin activation can become more reliant on ASH1L’s H3K36me2 to maintain transcriptional competency; knocking out ASH1L then delivers a second hit to the same transcriptional axis. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3741089/?utm_source=openai))
- WDR5 E58K and KMT2B R2712Q: WDR5 is a core WRAD subunit that binds the MLL “WIN” motif to assemble active H3K4 methyltransferase complexes; KMT2B (MLL2) is an H3K4‑me3 enzyme at bivalent/lineage promoters. While the specific functional impact of E58K or R2712Q is unknown here, any perturbation of WDR5–MLL or KMT2B function further tilts the balance toward dependence on alternative activators such as ASH1L. This makes ASH1L loss disproportionately harmful. (Mechanistic background on WDR5–MLL and KMT2B provided in the citations.) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2596411/?utm_source=openai))
- ASH1L E515K: E515 is far N‑terminal and well outside the catalytic SET domain (∼residues 2069–2288). Its impact is unclear, but even a mild functional hit could create “just‑enough” ASH1L activity for survival—until CRISPR‑KO removes the residual function entirely. This is a plausible sensitizer, though unproven for this exact variant. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4664444/?utm_source=openai))

A concrete model for ZR‑75‑1
- ZR‑75‑1, an ER+ luminal cell line, relies on a TRPS1/ER‑centered lineage program and shows top dependencies in chromatin assembly/activation (ASF1B, BRPF1), consistent with a state that requires active, open chromatin. ASH1L deposits H3K36me2 at regulatory elements to keep PRC2 off and to facilitate MLL/LEDGF‑supported transcription. In ZR‑75‑1, lesions in MEN1 (and variants in WDR5/KMT2B) likely weaken the H3K4 arm of activation, making the H3K36 arm (ASH1L) indispensable. KO of ASH1L removes H3K36me2, PRC2 spreads, ER/TRPS1 binding is perturbed, and cell‑cycle programs collapse—hence the “super‑sensitive” phenotype. ([genomebiology.biomedcentral.com](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-024-03415-3?utm_source=openai))

What you could test (to falsify/confirm this model)
- Rescue by ASH1L catalytic activity: Re‑express wild‑type vs catalytic‑dead ASH1L after CRISPR; only the catalytic enzyme should rescue if H3K36me2 is the key. This mirrors leukemia models where ASH1L catalytic activity is required. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8534482/?utm_source=openai))
- Chromatin consequences: After ASH1L KO, ChIP‑seq should show loss of H3K36me2 at enhancers/promoters, gain of H3K27me3 and increased PRC2 occupancy at the same loci; ATAC‑seq should show reduced accessibility at TRPS1/ER target sites. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21239496/?utm_source=openai))
- Genetic context: If menin/MLL axis impairment is part of the vulnerability, partial rescue might be seen by (i) menin re‑expression, or (ii) enhancing H3K4me3 at key promoters (e.g., via targeted epigenome editing), though this is exploratory. Background on menin/MLL provided in the references. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3741089/?utm_source=openai))
- Pharmacologic modifiers: If PRC2 encroachment drives lethality, an EZH2 inhibitor should partially mitigate the transcriptional collapse and viability loss after ASH1L depletion (prediction derived from the H3K36–PRC2 antagonism). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21239496/?utm_source=openai))

Notes on specific hits in your top‑10
- TRPS1: lineage‑specific dependency in luminal breast cancer; controls chromatin and ER binding; its centrality fits the model that open chromatin maintenance (via ASH1L) is essential. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30380416/?utm_source=openai))
- BRPF1: scaffold of KAT6A/KAT6B HAT complexes that write H3K23ac/propionylation at active chromatin; co‑dependency with ASH1L flags enhancer‑centric vulnerabilities. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9454415/?utm_source=openai))
- ASF1B: S‑phase H3–H4 chaperone promoting new histone acetylation; strong dependence suggests tight coupling between replication and chromatin maturation, increasing sensitivity to any perturbation that lets PRC2 invade active loci. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17107956/?utm_source=openai))

Key references for the mechanism and context
- H3K36 methylation antagonizes PRC2/H3K27me3; ASH1L contributes H3K36me2 at active regions. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21239496/?utm_source=openai))
- ASH1L activity is focused at regulatory elements of developmental genes; H3K36me2 remains at select sites even when other K36 writers are disabled. ([genomebiology.biomedcentral.com](https://genomebiology.biomedcentral.com/articles/10.1186/s13059-024-03415-3?utm_source=openai))
- ASH1L→H3K36me2→LEDGF/MLL coupling supports transcription (generalizable beyond leukemia). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27154821/?utm_source=openai))
- TRPS1 is a luminal breast cancer dependency and modulates ER binding and gene expression. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30380416/?utm_source=openai))
- BRPF1 scaffolds KAT6A/KAT6B acetyltransferase complexes that mark active enhancers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9454415/?utm_source=openai))
- Menin (MEN1) is the scaffold for MLL1/2 COMPASS‑like complexes that sustain H3K4me3 at lineage genes. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3741089/?utm_source=openai))
- WDR5 forms the WIN‑pocket hub that assembles MLL complexes; perturbation can compromise H3K4 methylation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2596411/?utm_source=openai))
- ASH1L catalytic domain mapping (to place E515K outside SET). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4664444/?utm_source=openai))

Bottom line: In ZR‑75‑1, a combination of (i) lineage‑program dependence (TRPS1/ER), (ii) broad reliance on chromatin‑activating machinery (ASF1B/BRPF1), and (iii) lesions in the MLL/menin axis likely makes ASH1L’s H3K36me2 the keystone that keeps the luminal transcriptional architecture PRC2‑resistant. Pull out that keystone (CRISPR‑KO of ASH1L), and the network collapses. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38377146/?utm_source=openai))